ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
he innovation could pave the way for early and low-cost screening of smoking exposure and second-hand smoke biomarkers
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The company says the platform offers improved manufacturability and functional advantages
For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms
Backed by a £680,000 grant from Leeds Hospitals Charity, the study is jointly led by academics and clinicians from the University of Leeds and Leeds Teaching Hospitals NHS Trust
Subscribe To Our Newsletter & Stay Updated
